CORT Resubmits Relacorilant NDA After Initial Setback, Stock Rises

What happened

Corcept Therapeutics announced plans to resubmit the NDA for relacorilant in Cushing's syndrome, following an earlier FDA action that likely resulted in a Complete Response Letter. The stock jumped on the news, but the resubmission confirms a delay and adds uncertainty to the regulatory timeline. The core Korlym franchise remains profitable but faces generic erosion and reimbursement pressure. Management must now address FDA concerns adequately to secure approval, which is no longer assured. The prior HOLD thesis had anticipated a decision by end-2025; this resubmission pushes that expectation out, reducing near-term upside.

Implication

For investors, the resubmission pushes back the potential approval of relacorilant, reducing the near-term catalyst that had supported premium valuation. The core Korlym franchise continues to face generic pressure and reimbursement headwinds, which may become more pronounced during the extended wait. While stock price popped on the resubmission news, the lack of details on FDA concerns and the risk of another rejection make a buy at current levels risky. Conservative investors should consider reducing positions until clarity emerges on the resubmission package and FDA feedback. Aggressive investors may see a potential binary play if they believe Corcept can successfully address deficiencies, but the risk/reward is now less favorable than before the CRL.

Thesis delta

The prior thesis anticipated a potential FDA decision by end-2025 with a chance of approval; the resubmission announcement confirms a prior rejection, shifting the probability of near-term approval lower. The binary risk previously highlighted has materialized in a negative outcome, extending the timeline and increasing the chance of a more restrictive label or additional delays. We now view the risk/reward as more balanced to negative in the short term, pending more details from the resubmission.